Dulaglutide (GLP-1 RA) significantly reduced the risk of primary endpoint (CV death, nonfatal MI and nonfatal stroke; and nonfatal stroke but not overall mortality, CV death, nonfatal MI, or hospitalization for UA or HF. Significantly reduced HbA1c. The gene discussed is GLP1R; the disease is Stroke.